Category: MS Drug Therapies

EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic

 April 22, 2021 * New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute…

Stuart Schlossman

DIY drug infusion that halves the risk of relapse to benefit hundreds of thousands of multiple sclerosis patients

 April 24, 2021 Monthly jab goes into the leg, arm or stomach using device similar to the EpiPen In trials,…

Stuart Schlossman

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

 Published: Apr 15, 2021 TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent…

Stuart Schlossman

Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of …

ROCKLAND, Mass.–(BUSINESS WIRE)–Apr 16, 2021– EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada,…

Stuart Schlossman

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor Fenebrutinib

 Fenebrutinib Phase III clinical trial programme Roche has an initiating a Phase III clinical trial programme for fenebrutinib, an investigational…

Stuart Schlossman

New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis

April 16, 2021 01:00 ET | Source: F. Hoffmann-La Roche Ltd 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no…

Stuart Schlossman

FDA Approves Ponvory (ponesimod) For Adults With Relapsing Forms of MS

 FDA APPROVED       Ponesimod Medication Description Description Ponesimod, sold under the brand name Ponvory, is a medication for…

Stuart Schlossman

Cladribine Personalized Dosing Well Tolerated and Efficacious in Multiple Sclerosis

Researchers found that 22 of 23 patients with elevated CSF NfL at baseline had normal levels at 2-year follow-up. Kimberly…

Stuart Schlossman

Listing of (14) MS educational Talks (Symptom related and more) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)- by @NeurologyLIVE

encephalitis. CNM-Au8 Displays Positive Interim Results in Multiple Sclerosis February 28, 2021 ByMatt Hoffman Clene Nanomedicine’s nanocatalyst agent CNM-Au8 displayed…

Stuart Schlossman

If you are a Bristol Myers Squibb (BMS) patient and lost your job and health insurance due to the COVID-19 pandemic, ,,,

During these challenging times, if you are a U.S. BMS patient and lost your job and health insurance due to the…

Stuart Schlossman

Categories

Latest Blog Posts